Avadel Pharmaceuticals 2025 Q3 Earnings Revenue Surpasses Estimates, Net Income Turns Positive

Avadel Pharmaceuticals (AVDL) reported fiscal 2025 Q3 earnings on Nov 4, 2025, with revenue exceeding expectations but net income swinging to a modest profit. The company raised full-year guidance to $275 million amid robust LUMRYZ growth and strategic catalysts.

Revenue

Avadel’s Q3 revenue surged 54.9% to $77.47 million, driven entirely by net product sales, which mirrored the total revenue figure. This marked a significant acceleration from $50.02 million in the prior-year period, reflecting strong demand for LUMRYZ and expanded patient access.

Earnings/Net Income

The company maintained a $0.00 EPS, missing estimates by $0.05, but achieved a net income of $20,000—a 100.8% positive swing from a $2.63 million loss in 2024 Q3. While revenue growth was robust, the EPS shortfall and modest net income highlight mixed performance.

Price Action

The stock edged up 0.59% in the latest trading day, 1.67% in the week, and surged 25.92% month-to-date.

Post-Earnings Price Action Review

The deep research logic is organized as follows: The user seeks to backtest AVDL’s 30-day post-earnings returns but lacks granular data. Available yearly closing prices (2022–2025) show a 80% YoY jump in 2025, though precise quarterly metrics are absent. Key drivers include the Q3 revenue beat, Alkermes acquisition, and Jazz settlement. Without daily earnings dates, a detailed backtest remains infeasible.

CEO Commentary

Avadel’s leadership highlighted LUMRYZ’s 55% YoY revenue growth and 48% patient base expansion. Strategic priorities include the pending $2.1 billion Alkermes acquisition (Q1 2026) and LUMRYZ’s expanded commercialization post-Jazz settlement.

Guidance

The company expects the Alkermes deal to close in Q1 2026, with REVITALYZ trial completion by year-end 2025. FY2025 revenue guidance remains raised to $275 million.

Additional News

1. M&A Activity: Alkermes agreed to acquire Avadel for $20/share ($2.1B valuation), pending regulatory approval.

2. Settlement: Resolved litigation with Jazz Pharmaceuticals, enabling LUMRYZ commercialization beyond narcolepsy by 2028.

3. Pipeline Expansion: Valiloxybate license acquisition from XWPharma and Phase 3 trial completion for idiopathic hypersomnia.